Form 4: Regeneron's President and CSO, George Yancopoulos, Disposes of Shares Under 10b5-1 Plan

George Yancopoulos, President and CSO of Regeneron Pharmaceuticals, sold shares of the company's common stock on May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 15, 2024, George Yancopoulos, the President and CSO of Regeneron Pharmaceuticals, sold shares of the company's common stock.
• The sales were executed under a plan intended to comply with Rule 10b5-1(c), which was adopted on February 14, 2024.
• The transactions involved multiple sales at varying prices, ranging from $965.69 to $989.28 per share.
• A total of 61,276 shares were sold on May 15, 2024.
• Following the reported transactions, Yancopoulos directly owns 836,383 shares of Regeneron common stock.
• He also indirectly owns shares through a 401(k) plan (5,903 shares), trusts for children (180,000 shares), a 2022 GRAT II (158,410 shares), and directly for children (18,148 shares).

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions.

Industry Context

Sales by insiders are common and often pre-planned to avoid accusations of trading on non-public information. The 10b5-1 plan allows corporate insiders to sell company stock over a predetermined period.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates